BASSANO DEL GRAPPA, Italy - E-FACTORY GROUP SRL announced expanded distribution of its NoMore Colds red light therapy device across non-European markets while revealing plans for a patented next-generation product paired with a companion mobile app, the company said Monday.
The Italian healthtech firm, which has sold more than 50,000 units globally since launching its drug-free nasal congestion device in 2023, strengthened packaging protocols and customer support systems to accommodate growing international demand. The timing coincides with increased consumer interest in non-pharmaceutical wellness alternatives, which market research firm Grand View Research projects will reach $7 trillion globally by 2025.
"We saw how many people live with chronic congestion and recurring colds, cycling through meds and sprays without lasting relief," said Riccardo, CEO of E-FACTORY GROUP. "Our goal was creating something natural, easy to use, and consistent - bringing clinic-grade innovation into a pocket-size device."
The company's forthcoming patented device will launch alongside a NoMore app designed to track user progress, offer optional clinician oversight, and provide exclusive discounts to community members. A limited early-access list has opened for customers in the United States, United Kingdom, and Canada, with staged rollouts planned based on regulatory timelines, though the company declined to specify exact launch dates.
The portable device weighs approximately 12 grams. It delivers a 10-minute daily red light therapy routine aimed at helping users manage stuffiness and sinus discomfort. According to data from the American Academy of Allergy, Asthma & Immunology, chronic sinusitis affects roughly 12 percent of American adults, creating sustained demand for alternative treatment options.
E-FACTORY GROUP has attracted early business-to-business interest from wellness clinics placing multi-unit orders for resale, though the company maintains its primary focus on direct-to-consumer sales. The red light therapy market itself has seen considerable growth, with Allied Market Research reporting the global sector could reach $181.4 million by 2032, up from $69.5 million in 2022.
The firm upgraded packaging integrity and clarified product instructions over the past quarter while reinforcing its 30-day money-back guarantee and one-year warranty programs. The device operates through three modes and comes with nasal adapters, a charging cable, and instructional materials, Company guidance recommends users consult healthcare providers before use during pregnancy, breastfeeding, or while taking medications.
The wellness device category has drawn both enthusiasm and skepticism. Research published in Photobiomodulation, Photomedicine, and Laser Surgery suggests photobiomodulation may offer therapeutic benefits for certain conditions, though clinical evidence remains mixed for specific applications like nasal congestion relief.
Based in Bassano del Grappa in northeastern Italy, E-FACTORY GROUP ships worldwide excluding European markets. The company emphasizes its wellness-oriented messaging avoids medical claims while maintaining safety-first guidance for users seeking drug-free alternatives to traditional congestion remedies.
The app's clinician oversight feature represents a notable shift for the direct-to-consumer brand, potentially positioning NoMore as a hybrid wellness-medical device, though regulatory classifications remain unclear as the product hasn't launched yet.
Media Contact
Company Name: Try NoMore
Contact Person: Media Relations
Email: Send Email
Country: Italy
Website: try-nomore.com